Seattle Genetics' Hodgkin's lymphoma drug wins U.S. approval

(Reuters) - U.S. regulators on Tuesday approved Seattle Genetics Inc's Adcetris as part of a chemotherapy cocktail to treat advanced Hodgkin's lymphoma in newly diagnosed patients, opening up a key market for the drugmaker.